ContraFect began a Phase 2 study to evaluate CF-301 as a treatment of Staphylococcus aureus bacteremia.
ContraFect (NASDAQ:CFRX) began a Phase 2 study to evaluate CF-301 as a treatment of Staphylococcus aureus bacteremia.
As quoted in the press release:
Staph aureus bacteremia and endocarditis are serious life threatening infections, associated with substantial morbidity and mortality despite currently available conventional antibiotics. This multicenter, randomized, double-blind, placebo-controlled study is designed to evaluate the potential for CF-301 to be used in addition to standard-of-care (SOC) antibiotics to significantly improve clinical success rates compared to SOC antibiotics alone. Safety, tolerability, and pharmacokinetics of CF-301 will also be evaluated in the study. The company expects to announce top line results in Q4 2018.
“We are very pleased to initiate the first clinical study of CF-301 in patients with S. aureusbacteremia. Based on the extensive amount of pre-clinical data generated, CF-301 has the potential to improve clinical outcomes for these patients by rapid bacterial killing, synergy with conventional antibiotics and clearance of biofilms that complicate Staph aureus infections, ” said Cara Cassino, M.D., EVP of Research and Development and Chief Medical Officer at ContraFect.